Arthur He Analyst PerformanceEquity Research Vice President at HC WainwrightArthur He is a stock analyst at HC Wainwright focused in the medical sector, covering 10 publicly traded companies. Over the past year, Arthur He has issued 19 stock ratings, including buy and hold recommendations. While full access to Arthur He's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Arthur He's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings29 Last 1 YearsBuy Recommendations86.21% 25 Buy RatingsCompanies Covered10 Unique Companies Ratings Distribution29RatingsDistribution of strong buy, buy, hold, and sell ratings by Arthur He.RatingPercentageCount Strong Buy0.0%0 ratings Buy86.2%25 ratings Hold13.8%4 ratings Sell0.0%0 ratingsOut of 29 total stock ratings issued by Arthur He at HC Wainwright, the majority (86.2%) have been Buy recommendations, followed by 13.8% Hold.Best & Worst CallsBest Call0000.0%ADAGApr 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ADAGJan 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ10 companiesArthur He, an analyst at HC Wainwright, currently covers 10 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical8 companies80.0%Miscellaneous1 company10.0%Manufacturing1 company10.0%Arthur He of HC Wainwright specializes in stock coverage within the Medical sector, with additional focus on and Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE6 companies60.0%MED - DRUGS2 companies20.0%Miscellaneous1 company10.0%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES1 company10.0% Arthur He's Ratings History at HC Wainwright Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsMSLESatellos Bioscience5/18/2026Reiterated Rating$7.20$11.00Buy$0.0000.00% ROIJBIOJade Biosciences4/27/2026Boost Price Target$24.98$45.00Buy$0.0000.00% ROINKTRNektar Therapeutics4/20/2026Boost Price Target$105.21$185.00Buy$0.0000.00% ROIMSLESatellos Bioscience3/30/2026Boost Price Target$6.19$11.00Buy$0.0000.00% ROIJBIOJade Biosciences3/25/2026Boost Price Target$13.26$35.00Buy$0.0000.00% ROISLDBSolid Biosciences3/23/2026Reiterated Rating$7.03$20.00Buy$0.0000.00% ROIVERAVera Therapeutics3/2/2026Boost Price Target$40.79$110.00Buy$0.0000.00% ROINKTRNektar Therapeutics2/10/2026Boost Price Target$52.44$165.00Buy$0.0000.00% ROIJBIOJade Biosciences1/7/2026Initiated Coverage$13.17$25.00Buy$0.0000.00% ROIJBIOJade Biosciences1/7/2026Initiated Coverage$13.19$25.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. NKTRNektar Therapeutics12/16/2025Boost Price Target$50.60$135.00Buy$0.0000.00% ROIVERAVera Therapeutics11/28/2025Reiterated Rating$33.33$90.00Buy$0.0000.00% ROIVERAVera Therapeutics11/10/2025Boost Price Target$24.19$90.00Buy$0.0000.00% ROIADAGAdagene8/15/2025Lower Price Target$2.01$7.00Buy$0.0000.00% ROILVTXLAVA Therapeutics8/5/2025Lower Price Target$1.51$1.24Neutral$0.0000.00% ROIAUPHAurinia Pharmaceuticals7/30/2025Reiterated Rating$8.94$17.00Buy$0.0000.00% ROIADAPAdaptimmune Therapeutics7/29/2025Reiterated Rating$0.10Neutral$0.0000.00% ROINKTRNektar Therapeutics6/24/2025Boost Price Target$22.60$120.00Buy$0.0000.00% ROISLDBSolid Biosciences6/17/2025Reiterated Rating$5.02$20.00Buy$0.0000.00% ROIPRMEPrime Medicine5/20/2025Downgrade$1.34Neutral$0.0000.00% ROIVERAVera Therapeutics5/5/2025Initiated Coverage$25.18$75.00Buy$00.0000.00% ROIADAGAdagene4/3/2025Reiterated Rating$1.64$8.00Buy$0.0000.00% ROIADAPAdaptimmune Therapeutics4/1/2025Lower Price Target$0.20$3.00Buy$0.0000.00% ROIPRMEPrime Medicine3/19/2025Reiterated Rating$1.76$10.00Buy$0.0000.00% ROISLDBSolid Biosciences3/10/2025Boost Price Target$5.42$20.00Buy$0.0000.00% ROIPRMEPrime Medicine3/3/2025Reiterated Rating$2.52$10.00Buy$0.0000.00% ROILVTXLAVA Therapeutics2/27/2025Reiterated Rating$1.35$1.50Neutral$0.0000.00% ROIADAGAdagene1/27/2025Boost Price Target$1.95$8.00Buy$0.0000.00% ROISLDBSolid Biosciences1/10/2025Reiterated Rating$3.60$16.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenJefferies Financial GroupWeiss RatingsUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.The Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
